Primed for at­tack: Vac­cine tech mak­er gets $11M shot to bat­tle in­fec­tious dis­ease

Tra­di­tion­al an­ti­body-based vac­cines, as a ba­sic prin­ci­ple, pre­vent in­fec­tion. UK-based Emergex’s tech­nol­o­gy doesn’t care if you do con­tract the in­fec­tion — it is en­gi­neered to en­sure …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.